Barclays PLC Immunovant, Inc. Call Options Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 15, 2024
BUY
$27.51 - $27.51 $3.19 Million - $3.19 Million
115,900 Added 137.81%
200,000 $5.7 Million
Q2 2024

Aug 14, 2024
BUY
$25.1 - $31.61 $2.11 Million - $2.66 Million
84,100 New
84,100 $2.22 Million
Q4 2023

Feb 15, 2024
BUY
$31.31 - $44.19 $18,786 - $26,514
600 Added 4.17%
15,000 $632,000
Q3 2023

Nov 07, 2023
BUY
$18.55 - $39.96 $267,120 - $575,424
14,400 New
14,400 $552,000

Others Institutions Holding IMVT

# of Institutions
212
Shares Held
66.9M
Call Options Held
2.3M
Put Options Held
631K
View Full List

About Immunovant, Inc.

IMVT Quotes by TradingView
  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email